Esperion Therapeutics (ESPR) Change in Accured Expenses (2012 - 2026)

Esperion Therapeutics' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$4.9 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 421.89% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.3 million (up 39.73% YoY) and the FY2025 annual result came in at $31.2 million, up 70.23% from the prior year.
• Change in Accured Expenses was -$4.9 million for Q1 2026 at Esperion Therapeutics, down from $12.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.2 million in Q3 2025 and bottomed at -$4.9 million in Q1 2026.
• A 5-year average of $4.2 million and a median of $1.2 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 690.34% — and 2026, when it sank 421.89%.
• Esperion Therapeutics' Change in Accured Expenses stood at $1.2 million in 2022, then surged by 566.8% to $8.2 million in 2023, then fell by 22.55% to $6.3 million in 2024, then surged by 100.41% to $12.7 million in 2025, then plunged by 138.24% to -$4.9 million in 2026.
• Business Quant data shows ESPR's Change in Accured Expenses at -$4.9 million in Q1 2026, $12.7 million in Q4 2025, and $21.2 million in Q3 2025.